Telomir Pharmaceuticals
Baltimore
About Telomir Pharmaceuticals
Telomir Pharmaceuticals develops a novel treatment that binds critical metals to interrupt enzyme function and returns cellular metals like Iron, copper, and zinc to homeostasis. Telomir 1 is a small molecule being developed as the regulator of telomere length and genomic stability.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $9.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2025)
- Ticker: nasdaq:TELO
- Website: telomirpharma.com
- Phone: 813-864-2562
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/telomir-pharmaceuticals-78731 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.